29QJ | pdb_000029qj

Respiratory syncytial virus fusion protein N-terminal heptad repeat domain in complex with Double stapled peptide 4/4g


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.32 Å
  • R-Value Free: 
    0.232 (Depositor), 0.218 (DCC) 
  • R-Value Work: 
    0.205 (Depositor), 0.199 (DCC) 
  • R-Value Observed: 
    0.206 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 29QJ

This is version 1.0 of the entry. See complete history

Literature

Double-Stapled Peptide Scan Yields Potent Fusion Inhibitors of Respiratory Syncytial Virus.

Pidoux, N.Roh, L.Nicolet, N.Marti, R.Le Rouzic, A.Prompt, C.Fix, J.Duquerroy, S.Rey, F.Rameix-Welti, M.A.Keck, M.Barbe, P.Garcin, D.Mottet-Osman, G.Larcher, T.Galloux, M.Nyanguile, O.

(2026) J Med Chem 

  • DOI: https://doi.org/10.1021/acs.jmedchem.5c02932
  • Primary Citation Related Structures: 
    29QJ, 9RA5

  • PubMed Abstract: 

    Respiratory syncytial virus infection (RSV) is a major global health concern, particularly in infants and elderly populations. In this work, we have screened and identified 3 double-stapled peptides derived from a minimal domain of the RSV F heptad repeat, namely 3/4i , 3/4m , and 4/4g , which are potent inhibitors of RSV fusion and remain active against viral escape mutants resistant to small-molecule fusion inhibitors. Our structural activity relationship (SAR) analysis demonstrates that combining a limited set of staples is sufficient to achieve high antiviral potency. X-ray crystallography revealed that the enhanced potency of 3/4i and 3/4m primarily arises from strong hydrophobic interactions between the N-terminal staple and the trimeric HR1 coiled coil of RSV F. In vivo pharmacokinetic, imaging, and feasibility studies in RSV-infected Balb/c mice further support intranasal administration as a promising route for delivering these stapled peptides to the lung, highlighting their potential as therapeutics against RSV.


  • Organizational Affiliation
    • HES-SO Valais-Wallis, Institute of Life Sciences, HES-SO University of Applied Sciences Western and Arts Switzerland, rue de l'Industrie 19, Sion 1950, Switzerland.

Macromolecule Content 

  • Total Structure Weight: 8.03 kDa 
  • Atom Count: 614 
  • Modeled Residue Count: 68 
  • Deposited Residue Count: 75 
  • Unique protein chains: 2

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Fusion glycoprotein F153Human respiratory syncytial virus AMutation(s): 2 
UniProt
Find proteins for P03420 (Human respiratory syncytial virus A (strain A2))
Explore P03420 
Go to UniProtKB:  P03420
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP03420
Sequence Annotations
Expand
Reference Sequence
Find similar proteins by:  Sequence   |   3D Structure  
Entity ID: 2
MoleculeChains  Sequence LengthOrganismDetailsImage
Double stapled peptide 4/4gB [auth D]22human respiratory syncytial virusMutation(s): 0 

Small Molecules

Modified Residues  1 Unique
IDChains TypeFormula2D DiagramParent
MK8
Query on MK8
B [auth D]L-PEPTIDE LINKINGC7 H15 N O2LEU

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.32 Å
  • R-Value Free:  0.232 (Depositor), 0.218 (DCC) 
  • R-Value Work:  0.205 (Depositor), 0.199 (DCC) 
  • R-Value Observed: 0.206 (Depositor) 
Space Group: H 3 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 41.083α = 90
b = 41.083β = 90
c = 200.844γ = 120
Software Package:
Software NamePurpose
BUSTERrefinement
autoPROCdata processing
Aimlessdata scaling
PHASERphasing
XDSdata scaling
STARANISOdata scaling

Structure Validation

View Full Validation Report



Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Other governmentSwitzerlandHES-SO 78166/IA-INTERDISC17-2

Revision History  (Full details and data files)

  • Version 1.0: 2026-06-10
    Type: Initial release